Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Specimen Handling 415 Magnetic Resonance Spectroscopy 332 pembrolizumab 261 Biopsy 227 Carboplatin 216 Cisplatin 179 Cyclophosphamide 174 Paclitaxel 148 Nivolumab 135 Gemcitabine 130 Radiotherapy 120 Dexamethasone 105 Bevacizumab 101 fludarabine 95 Radiation 94 Fluorouracil 93 Pemetrexed 88 Doxorubicin 88 Docetaxel 83 Rituximab 82 venetoclax 81 durvalumab 81 Oxaliplatin 81 Leucovorin 76 atezolizumab 68 Lenalidomide 66 Capecitabine 66 Prednisone 65 Etoposide 64 Vincristine 62

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × efgartigimod alfa × 30 days × Clear all

NCT07217587 2026-05-08

EPIC

Janssen Research & Development, LLC

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡